Educational content only. Not medical advice. Consult a qualified physician.
PE-22-28 (Spadin analog) peptide
CognitiveResearch-only. Preclinical compound. No human clinical trials. Not FDA-approved or under regulatory review.

PE-22-28

PE-22-28 (Spadin analog)

PE-22-28 is a synthetic heptapeptide derived from spadin, which itself is a fragment of the sortilin propeptide. It acts as an antagonist of the TREK-1 potassium channel, a validated target for antidepressant activity. Research suggests it may have rapid-onset antidepressant-like effects in animal models, acting within days rather than weeks.
Reported Benefits

Potential Benefits

  • Animal studies suggest antidepressant-like effects through TREK-1 channel blockade
  • Preclinical data indicates rapid onset of action (days rather than weeks) compared to traditional antidepressants
  • Research suggests potential for neurogenesis in the hippocampus
  • May improve stress resilience in animal models
  • Does not appear to cause the side effects associated with traditional SSRI medications in animal studies
Research Dosing

Recommended Starting Dose

Not established for humans; animal studies use doses that are not directly translatable

Based on published research protocols. Not a prescription.

Dosing Protocol

No established human dosing protocol. This peptide is referenced in animal research only. Anyone considering this compound should understand that no human safety or efficacy data exists.

DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.

Research Timeline

Expected Timeline

Phase 1

Animal studies suggest effects within 4-7 days. No human timeline data exists.

Regulatory

Research Status

Research-only. Preclinical compound. No human clinical trials. Not FDA-approved or under regulatory review.

The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.

Safety Profile

Potential Side Effects

  • No published human safety data
  • All current data is from animal models
  • Unknown interactions with existing psychiatric medications
  • Long-term effects are completely uncharacterized
  • Quality and purity concerns with research-grade compounds
Related Research

More in Cognitive

Medical Disclaimer

EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.